The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Parkinson's disease (PD) is a heterogenous disease with a varying age of onset, symptoms,
and rate of progression. This heterogeneity requires the use of a variety of animal models to …

Background In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via
an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor …

Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the
second most common neurodegenerative disease after Alzheimer's. Typical …

Background There is an urgent need for therapies that slow or reverse the progression of
Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating …

Parkinson's disease (PD) is a progressive neurodegenerative disorder resulting from the
death of dopamine neurons in the substantia nigra pars compacta. Our understanding of PD …

Parkinson's disease (PD) is the second-leading cause of dementia and is characterized by a
progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of …

Microglia are the main immune cells in the brain, playing a role in both physiological and
pathological conditions. Microglial involvement in neurodegenerative diseases is well …

Therapies capable of decelerating, or perhaps even halting, neurodegeneration in
Parkinson's disease (PD) remain elusive. Clinical trials of PD gene therapy testing the …

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD),
Huntington's disease (HD), multiple sclerosis (MS), spinal cord injury (SCI), and amyotrophic …